Updated on 28 November 2012
PAREXEL, National Taiwan University Hospital collaborate on clinical research
Singapore: Taiwan's PAREXEL International, a biopharmaceutical services provider, and National Taiwan University Hospital (NTUH) have collaborated to provide drug development services in Taiwan.
"Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of phase I-to-IV clinical trials in a rapidly growing market," said Mr Joe Avellone, corporate senior vice president, clinical research services, PAREXEL International. "The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients' programs in the region and help them to compete more effectively in the global marketplace."
"We are delighted to collaborate with PAREXEL, a world-leading biopharmaceutical services provider" said Ming-Fong Chen, superintendent, National Taiwan University Hospital. "PAREXEL has a wealth of experience in both local and global clinical development programs. This partnership will bring opportunities for both PAREXEL and NTUH to leverage our combined expertise in order to accelerate clinical development programs in Taiwan and meet patients' need for more effective treatments."
The alliance will drive greater efficiency for biopharmaceutical sponsors worldwide. As a center of excellence for clinical trials in Taiwan and the Asia Pacific region, the National Taiwan University Hospital is ideally positioned to support PAREXEL in delivering a superior clinical development service to local and global biopharmaceutical companies. The combined experience and development expertise of the two organizations will help to create innovative solutions for biopharmaceutical companies looking to develop or market their products within this important region.